The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Cysteinyl‐leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends
Abstract
Cysteinyl‐leukotrienes (cysteinyl‐LTs), that is, LTC 4, LTD 4, and LTE 4, trigger contractile and inflammatory responses through the specific interaction with G protein‐coupled receptors (GPCRs) belonging to the purine receptor cluster of the rhodopsin family, and identified as CysLT receptors (CysLTRs). Cysteinyl‐LTs have a clear role in pathophysiological conditions such as asthma and allergic rhinitis (AR), and have been implicated in other inflammatory conditions including cardiovascular diseases, cancer, atopic dermatitis, and urticaria. Molecular cloning of human CysLT 1 R and CysLT 2 R subtypes has confirmed most of the previous pharmacological characterization and identified distinct expression patterns only partially overlapping. Interestingly, recent data provide evidence for the immunomodulation of CysLTR expression, the existence of additional receptor subtypes, and of an intracellular pool of CysLTRs that may have roles different from those of plasma membrane receptors. Furthermore, genetic variants have been identified for the CysLTRs that may interact to confer risk for atopy. Finally, a crosstalk between the cysteinyl‐LT and the purine systems is being delineated. This review will summarize and attempt to integrate recent data derived from studies on the molecular pharmacology and pharmacogenetics of CysLTRs, and will consider the therapeutic opportunities arising from the new roles suggested for cysteinyl‐LTs and their receptors. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 4, 469–527, 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043 · cited 1×
“Stroke and coronary heart disease (CHD) are the leading causes of death and disability among adults.(413) Cerebral ischemia is clinically characterized by reduced blood circulation, and the resulting hypoperfusion can involve thewhole brain, or part of it, thus causing a global or a focal ischemia.”
BackgroundProstaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate
Brash, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23679 · Cited by 1,335
(1996) · European Respiratory Journal · doi:10.1183/09031936.96.09040687 · Cited by 1,002
Mehrabian, M., Allayee, H., Wong, J., Shih, W., Wang, X.-P., Shaposhnik, Z., Funk, C. D., & Lusis, A. J. (2002) · Circulation Research · doi:10.1161/01.res.0000028008.99774.7f · Cited by 422
Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex
Zhang, B., Cunningham, M. A., Nichols, W. C., Bernat, J. A., Seligsohn, U., Pipe, S. W., McVey, J. H., Schulte-Overberg, U., de Bosch, N. B., Ruiz-Saez, A., et al. (2003) · Nature Genetics · doi:10.1038/ng1153 · Cited by 309
Keogh, K. A., & Specks, U. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00359-0 · Cited by 290
5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation
Catalano, A., Rodilossi, S., Caprari, P., Coppola, V., & Procopio, A. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600502 · Cited by 123 · cited 1×
“Anumber of observations document that 5-LO and its productsmay be relevant in carcinogenesis and tumor progression.(432,433) 5-LO is expressed by a broad variety of cancer cells and tissues,(432) although the sequelae of events connecting cancer development and 5-LO gene expression are unknown.”
Background
Cited by
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 614
Ciana, P., Fumagalli, M., Trincavelli, M. L., Verderio, C., Rosa, P., Lecca, D., Ferrario, S., Parravicini, C., Capra, V., Gelosa, P., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601341 · Cited by 438
Self-citationEpoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology
Imig, J. D. (2012) · Physiological Reviews · doi:10.1152/physrev.00021.2011 · Cited by 365
Biosynthesis and metabolism of leukotrienes
Murphy, R. C., & Gijón, M. A. (2007) · Biochemical Journal · doi:10.1042/bj20070289 · Cited by 319
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Bäck, M., Powell, W. S., Dahlén, S., Drazen, J. M., Evans, J. F., Serhan, C. N., Shimizu, T., Yokomizo, T., & Rovati, G. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12665 · Cited by 217
Self-citation
Metadata
- Authors
- Capra, V., Thompson, M. D., Sala, A., Cole, D. E., Folco, G., & Rovati, G. E.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2006-08-07
- Volume
- 27
- Issue
- 4
- Pages
- 469-527
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2163744692
- Cited by
- 168
- References
- 11
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.